Altindag

Researchers are conducting a Phase 3, randomized, double-blind, controlled study to evaluate the safety and effectiveness of DefenCath compared with heparin in adults who receive home Total Parenteral Nutrition TPN via a Central Venous Catheter CVC. The study aims to reduce central line-associated bloodstream infections CLABSIs in this population by comparing these two catheter lock solutions. Participants will be randomly assigned to receive either DefenCath, a catheter lock solution containing taurolidine and heparin, or heparin alone. The study is adaptive and involves two groups across multiple centers. Treatments are administered through the central venous catheter as part of routine TPN care, with participants or their caregivers managing the instillation and aspiration according to their regular TPN schedule. The study duration extends up to 12 months for each participant. During the study, participants or their caregivers will maintain a daily diary and self-administer assessments related to catheter use and infections. Researchers will monitor the occurrence of bloodstream infections as the main outcome within 12 months. Additional evaluations include tracking adverse events, laboratory results, vital signs, and physical exam findings. The study is designed to ensure participant safety and thorough follow-up throughout the treatment period.

Renal transplantation is a major surgery linked to significant pain after the operation due to the incision and tissue involvement. Managing this pain well is important to help patients recover faster, reduce opioid use, and avoid side effects. This trial evaluates the pain control benefits of using a transversalis fascia plane block compared to standard pain management in patients undergoing kidney transplant surgery. Participants are randomly assigned to one of two groups. One group receives an ultrasound-guided transversalis fascia plane block, where 30 ml of 0.25% bupivacaine is injected near abdominal muscles on the surgery side, alongside standard pain medications given during surgery. The other group receives the same standard pain medications but no nerve block. Both groups get intravenous tramadol before and after surgery and intravenous paracetamol at the end. During the study, pain scores on the day of surgery are closely monitored, along with opioid use during and after the operation. Researchers use ultrasound to guide the nerve block and confirm medication spread. The study uses triple masking and randomization to compare outcomes fairly. The goal is to assess how well the nerve block controls pain and reduces opioid needs after kidney transplant surgery.

Researchers are evaluating the effects of two regional anesthesia techniques, intrathecal morphine and bi-level erector spinae plane block, on postoperative pain relief in living liver donors. The study focuses on improving pain management after donor hepatectomy, which is crucial for donor recovery, quality of life, and reducing the risk of chronic pain. This trial compares these methods to determine which better controls pain and reduces opioid use after surgery. Participants will receive either an intrathecal injection of 300 mcg morphine at the L3-L4 or L4-L5 spinal level or a bi-level erector spinae plane block. The block involves ultrasound-guided injections of 0.25% bupivacaine at two levels on both sides of the spine. Both groups will also receive intravenous meperidine during surgery and dexketoprofen twice daily after surgery as part of multimodal pain control. During the study, pain scores on the day of surgery will be measured to assess analgesic effectiveness. Researchers will also monitor opioid use during and after surgery to evaluate pain management. The trial involves randomized, double-blind assignment to treatment groups and includes adults aged 18 to 65 years with specific health criteria. The study is sponsored by Ankara Etlik City Hospital and is expected to run until July 2026.

Inguinal hernia is a common surgical condition in children, and this trial evaluates two types of nerve blocks for managing pain after a minimally invasive surgery called percutaneous internal ring suturing PIRS. Researchers aim to compare the pain relief effects of rectus sheath block and caudal epidural block in pediatric patients undergoing this procedure. The study focuses on reducing the need for opioids after surgery by providing effective pain control with these nerve blocks. Participants will receive one of two nerve block procedures during PIRS surgery. One group will get a rectus sheath block, where a local anesthetic called bupivacaine is injected under ultrasound guidance on both sides of the abdomen. The other group will receive a caudal epidural block, involving the insertion of a needle near the sacral area to deliver bupivacaine. Both groups also receive paracetamol during surgery to help manage pain. Children in the study, aged 1 to 8 years, will be monitored on the day of surgery for pain levels using pain scores. Researchers will also watch for side effects like nausea and vomiting and track how soon children can get up and move after surgery. The study is randomized and double-blinded to fairly compare the two nerve block methods. The entire participant involvement covers the operation day and immediate postoperative period, focusing on safety and effectiveness of pain control.

Researchers are evaluating the pain relief effectiveness of two types of nerve blocksthe serratus posterior superior intercostal plane block and the erector spinae plane blockcompared to no nerve block in patients undergoing anterior cervical discectomy. This surgery is done to relieve pressure on nerves caused by cervical disc disease using a microscopic approach from the front of the neck. The study aims to find which nerve block offers better pain control after surgery, potentially reducing opioid use and related risks. Participants are randomly assigned to one of three groups one receiving the serratus posterior superior intercostal plane block with 30 ml of 0.25% bupivacaine under ultrasound guidance, another receiving the erector spinae plane block with the same dosing and method, and a control group undergoing surgery without a peripheral nerve block. All groups receive intravenous analgesics during surgery and multimodal pain management with paracetamol and dexketoprofen after surgery. During the study, patients will be monitored for pain scores on the day of surgery, and researchers will track opioid use during and after the operation. The study includes assessments of intraoperative remifentanil and tramadol consumption. The trial uses quadruple masking to reduce bias and will continue until November 2025, involving adults aged 18 to 80 years with specific health criteria.

Researchers are investigating how certain preoperative inflammatory biomarkers relate to the occurrence of postoperative nausea and vomiting PONV in children undergoing orchiopexy, a common surgery for treating cryptorchidism. This observational study focuses on children aged 1 to 8 years, exploring if markers like neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio can help predict PONV after surgery. Before surgery, blood samples will be taken to measure various inflammatory indicators such as NLR, PLR, systemic immune-inflammation index, MLR, and systemic inflammation response index. The study does not involve any experimental drugs or devices and all procedures will be part of the standard perioperative care during the elective orchiopexy. Participants will be monitored for the incidence of nausea and vomiting within six hours after surgery. Researchers will also track the need for antiemetic treatment during this period. The study aims to better understand how inflammation may contribute to PONV in pediatric patients, with the total participation covering preoperative assessment through early postoperative recovery.

Researchers are studying an experimental drug called ubamatamab in adult participants with advanced ovarian cancer, including primary peritoneal and fallopian tube cancers. The study aims to evaluate how safe and tolerable ubamatamab is when used alone or in combination with other anti-cancer drugs such as bevacizumab, cemiplimab, fianlimab, REGN10597, and pegylated liposomal doxorubicin PLD. This phase 2 trial also investigates side effects, drug levels in the blood, and immune responses against the study drugs. Participants receive ubamatamab either alone or combined with other specified cancer drugs according to the study protocol. The trial is randomized with multiple experimental arms, each testing different combinations of ubamatamab and additional agents. Treatments are administered per protocol, and the trial includes various schedules and dosing regimens based on the assigned group. Throughout the study, participants undergo regular assessments including tumor response evaluation using RECIST 1.1 criteria, measurements of cancer antigen CA-125 levels, and monitoring for adverse events. Blood samples are collected to measure drug concentrations and detect antibodies against the investigational drugs. Safety is closely monitored for up to three years, and the main outcome is the objective response rate assessed by investigators.

Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.

Researchers are evaluating treatments for patients newly diagnosed with Peripheral T-Cell Lymphoma PTCL in a phase 3 study. The trial aims to find the best dose of two drugs, Belinostat and Pralatrexate, combined with chemotherapy regimens CHOP or COP, focusing on safety and effectiveness. The study compares two experimental combinations against the standard CHOP regimen to see which improves progression-free survival in PTCL patients. The study has two parts. Part 1 tests two dose levels of Belinostat with CHOP and Pralatrexate with COP in five groups to determine the safest and most suitable doses. Part 2 randomizes patients into three groups Belinostat plus CHOP, Pralatrexate plus COP, and CHOP alone, with treatments given in up to six cycles spaced 21 days apart. Belinostat and Pralatrexate are administered intravenously with specific schedules alongside chemotherapy drugs. The study includes detailed dosing and administration plans for each group. Participants undergo up to 28 days of screening, followed by treatment cycles lasting about 18 weeks. Tumor assessments occur regularly during treatment and for up to three years after, with follow-up visits every six months until five years. Researchers collect data on progression-free survival, overall survival, and safety. Long-term monitoring includes phone follow-ups to track outcomes. Participants are closely monitored through clinical evaluations, laboratory tests, and imaging throughout the study.